Actinium announces fda clearance of iomab-act targeted conditioning ind application for sickle cell disease patients undergoing bone marrow transplant in collaboration with columbia university

- sickle cell disease affects approximately 100,000 patients in the u.s. annually and is a debilitating and life-threatening condition with high unmet need - current conditioning with non-targeted chemotherapies provides limited access to potentially curative bone marrow transplant and recently approved gene therapies for sickle cell disease patients - initial trial focused on conditioning for bone marrow transplant intended to inform subsequent gene therapy conditioning study and provide broader access to cellular therapy for sickle cell patients new york , july 25, 2024 /prnewswire/ -- actinium pharmaceuticals, inc. (nyse american: atnm) (actinium or the company), a leader in the development of antibody radiation conjugates (arcs) and other targeted radiotherapies, today announced the fda clearance of an investigational new drug (ind) application to study iomab-act for targeted conditioning prior to a bone marrow transplant (bmt), in patients with sickle cell disease. the study will be conducted in collaboration with the columbia university and led by markus mapara, m.d.
ACT Ratings Summary
ACT Quant Ranking